Suppr超能文献

肿瘤浸润肥大细胞预测胆道癌患者的预后和吉西他滨为基础的辅助化疗获益。

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.

机构信息

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.

出版信息

BMC Cancer. 2018 Mar 21;18(1):313. doi: 10.1186/s12885-018-4220-1.

Abstract

BACKGROUND

Recent studies have reported TIMs play an important role in tumors progression or regression, but the effect of TIMs in biliary tract cancer remains unclear. The aim of this study is to investigate the prognostic value of tumor infiltrating mast cells (TIMs) and its influence on gemcitabine-based adjuvant chemotherapy (ACT) benefits in biliary tract cancer patients after surgery.

METHODS

TIMs were evaluated by immunohistochemical staining of tryptase in 250 patients with resected gallbladder carcinoma (GBC) or extrahepatic bile duct carcinoma (EBDC) from Zhongshan Hospital. The relationships between TIMs and clinicopathological factors and postoperative prognosis were analyzed respectively.

RESULTS

High TIMs infiltration was significantly correlated with prolonged overall survival (OS). Furthermore, multivariate analysis indicated TNM stage and TIMs as independent prognostic factors for OS. Patients with high TIMs infiltration appeared to significantly benefit from Gemcitabine-based ACT in the discovery and validation cohorts. Spearman analysis identified that TIMs infiltration were positively correlated with anti-tumor CD8+ T cells.

CONCLUSION

TIMs infiltration is an independent favorable prognostic factor in GBC and EBDC patients, which could better stratify patients with different prognosis and predict benefit from gemcitabine-based ACT.

摘要

背景

最近的研究报告称 TIMs 在肿瘤的进展或消退中发挥重要作用,但 TIMs 在胆管癌中的作用尚不清楚。本研究旨在探讨肿瘤浸润肥大细胞(TIMs)的预后价值及其对手术后接受吉西他滨为基础的辅助化疗(ACT)的胆管癌患者获益的影响。

方法

本研究对中山医院 250 例接受胆囊癌(GBC)或肝外胆管癌(EBDC)切除术的患者的组织进行了 tryptase 的免疫组化染色,以评估 TIMs。分别分析 TIMs 与临床病理因素和术后预后的关系。

结果

高 TIMs 浸润与总生存期(OS)延长显著相关。此外,多因素分析表明 TNM 分期和 TIMs 是 OS 的独立预后因素。高 TIMs 浸润的患者在发现队列和验证队列中均明显受益于吉西他滨为基础的 ACT。Spearman 分析表明 TIMs 浸润与抗肿瘤 CD8+T 细胞呈正相关。

结论

TIMs 浸润是 GBC 和 EBDC 患者的独立预后良好因素,可更好地对具有不同预后的患者进行分层,并预测接受吉西他滨为基础的 ACT 的获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2024/5863450/36e11f6c6f25/12885_2018_4220_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验